Skip to main content

Table 1 Clinical and pathological characteristics of MIBC patient cohorts in this study

From: Calculated identification of mutator-derived lncRNA signatures of genomic instability to predict the clinical outcome of muscle-invasive bladder cancer

Covariates Training cohort (n = 200) Testing cohort (n = 199) TCGA cohort (n = 399) P-value
Age, no (%)     
 Young (≤ 65) 74 (37%) 85 (42.71%) 159 (39.85%) 0.2876
 Old (> 65) 126 (63%) 114 (57.29%) 240 (60.15%)  
Gender, no (%)     
 Female 57 (28.5%) 48 (24.12%) 105 (26.32%) 0.3791
 Male 143 (71.5%) 151 (72.88%) 294 (73.68%)  
Grade, no (%)     
 High Grade 189 (94.5%) 187 (93.97%) 376 (94.24%) 0.8185
 Low Grade 9 (4.5%) 11 (5.53%) 20 (5.01%)  
 Unknown 2 (1%) 1 (0.5%) 3 (0.75%)  
Stage, no (%)     
 Stage II 64 (32%) 62 (31.16%) 126 (31.58%) 0.9413
 Stage III–IV 135 (67.5%) 136 (68.34%) 271 (67.92%)  
 Unknown 1 (0.5%) 1 (0.5%) 2 (0.5%)  
T, no (%)     
 T2 62 (31%) 55 (27.64%) 117 (29.32%) 0.5967
 T3–4 123 (61.5%) 126 (63.32%) 249 (62.41%)  
 Unknown 15 (7.5%) 18 (9.05%) 33 (8.27%)  
M, no (%)     
 M0 89 (44.5%) 103 (51.76%) 192 (48.12%) 0.8268
 M1 6 (3%) 5 (2.51%) 11 (2.76%)  
 Unknown 105 (52.5%) 91 (45.73%) 196 (49.12%)  
N, no (%)     
 N0 120 (60%) 113 (56.78%) 233 (58.4%) 0.872
 N1–3 63 (31.5%) 63 (31.66%) 126 (31.58%)  
 Unknown 17 (8.5%) 23 (11.56%) 40 (10.03%)  
Fustat, no (%)     
 Alive 114 (57%) 109 (54.77%) 223 (55.89%) 0.7286
 Dead 86 (43%) 90 (45.23%) 176 (44.11%)